Hematology Diagnostics Market Research Report: Forecast (2023-2028)
Hematology diagnostics is the study of blood and blood disorders. It is used to diagnose, monitor and treat various ailments and conditions that affect the blood, including anemia, bleeding diseases, and blood cancers such as leukemia and lymphoma. Diagnostic tests are used to measure levels of red and white blood cells, platelets, hemoglobin, and other blood components. In addition, tests can detect abnormalities such as abnormal shapes, sizes, numbers of blood cells, and changes in blood clotting factors. Imaging tests, such as ultrasound and MRI, may also be used to help diagnose and monitor blood disorders.
The Global Hematology Diagnostics Market is projected to grow at a CAGR of around 6.9% during the forecast period, i.e., 2023-28. Hematology diagnostics require blood collection from patients using venipuncture or finger-prick methods, centrifugation to separate the blood's constituents, and quantitative or qualitative analysis. Hematology tests use various In-Vitro Diagnostic (IVD) techniques to identify issues with Red Blood Cells (RBCs), White Blood Cells (WBCs), lymph plasma, and platelets. These techniques include flow cytometry, blood analysis, immunodiagnostics, hemostasis, and molecular diagnostics.
For instance, anemia, an iron deficiency disease brought on by improper diet & nutrition, is most prevalent in the Middle East and Africa area. These procedures can identify physiological flaws early and treat them to prevent problems with motor and cognitive development.
|Study Period||Historical Data: 2018-21|
|Base Year: 2022|
|Forecast Period: 2023-28|
|Regions Covered||North America: USA, Canada, Mexico|
|Europe: Germany, UK, France, Italy, Spain|
|Asia-Pacific: China, India, Japan, South Korea, Australia|
|South America: Brazil, and Argentina|
|Middle East & Africa: UAE, Saudi Arabia|
|Key Companies Profiled||Abbott Laboratories, Mindray Medical International, Siemens Healthneers, BioSystems, BioRad Laboratories, Horiba, Symex Corporation, Nihon Kohden Corpration, Danaher Corporation, F. Hoffman-La-Roche Ltd.|
|Unit Denominations||USD Million/Billion|
The prime factors contributing to the growth of the market across the globe are the technological advancements for new automated analyzers & testers and rising blood-related disorders across both children & elders. Moreover, the rising geriatric population & the number of blood disorder-related incidents are other crucial aspects likely to surge the overall market growth of hematology diagnostics across the globe. In addition, increasing consumer awareness of blood diseases is anticipated to boost market growth significantly. Furthermore, in the upcoming years, the players competing in the market may benefit from increased investment in research & development activities to produce new diagnostic solutions.
Key Driver: The Rising Incidence of Blood Diseases Such as Cancer
The prevalence of blood disorders like hemophilia, thalassemia, and anemia is rising, significantly impacting the demand for hematology diagnostics. For example, every year, anemia is identified in about 29% of women and 38% of pregnant women, according to the National Institutes of Health (NIH). Thus, the increasing prevalence of blood-related disorders around the globe is driving their adoption worldwide. Early diagnosis can reduce mortality rates by preventing the disorder's long-term negative impacts.
In addition, hematologic tests can also reliably diagnose blood glucose diseases like diabetes, hypotension, and hypoglycemia. Backed by these aspects, the adoption of such tests is burgeoning in nations with high diabetes prevalence, thereby propelling market growth in the long run.
Possible Restraint: Escalating Medical Burden Due to Inadequate Insurance Coverage
Medical expenses heavily burden patients due to diagnostic tools like hematology analyzers. As a result, escalating hematology diagnostic costs and insufficient healthcare insurance coverage for these diagnostic procedures in many regions are prime factors anticipated to restrain market revenue growth in the coming years. Other than this, the industry is also anticipated to be significantly hindered by a lack of operational efficiency, trained professionals, and high-end hardware and software installed in flow cytometers and analyzers.
Growth Opportunity: Constant Technological Advancements in Diagnostic Techniques
Blood tests are increasingly being used for early leukemia detection and treatment as leukemia's prevalence among the world's population rises. According to American Cancer Society (ACS) data, 48% of all blood cancers are lymphomas. In addition to usage in cancer, such procedures use blood as a test sample for diagnosing conditions like diabetes, coronary heart disease, thalassemia, and thrombocytopenia. Citing its expansive adoption, market players have introduced several technological advancements in diagnostic techniques, leading to point-of-care tests and automated hematology diagnosis, consequently driving market growth across the world.
Based on End User,
The Hospitals and Clinics acquired the largest market share in the historical period; however, the diagnostic labs are predicted to proliferate during the projection period. It owes principally to the expansion of diagnostic facilities and the accessibility of cutting-edge equipment. Also, diagnostic instrument automation is likely to lower the cost of these tests, increasing their demand in the future.
Moreover, rising R&D initiatives demonstrating the effectiveness of hematology analyzers will probably positively influence their adoption in hospitals, clinics, and labs. For instance, automated hematologic analyzers are frequently used in medical laboratories, according to a paper titled "Establishment of better review criteria for hematology analyzers in cancer hospitals," published in February 2021.
Geographically, the Global Hematology Diagnostics Market expands across:
Europe is expected to account for a steady revenue growth rate during the forecast period. This is a result of rising healthcare expenditure in the region's nations as well as rising rates of blood disorders like thalassemia and hemophilia. In addition, chronic disease management has become a top priority in many European nations' health policies, as chronic diseases are a significant cause of mortality and morbidity in the continent.
Strong market players focusing on improving hematological diagnostics products and forming distribution alliances are also anticipated to significantly impact this regional market's revenue development. In addition, the region's extending leukemia incidence is driving up demand for hematology diagnostics.
Recent Developments in the Global Hematology Diagnostics Market
Gain a Competitive Edge with Our Global Hematology Diagnostics Market Report
Frequently Asked Questions
A. The Hematology Diagnostics Market is projected to grow at a CAGR of around 6.9% during 2023-28.
A. Rising incidence of blood diseases such as cancer is expected to drive the hematology diagnostics market during 2023-28.
A. Abbott Laboratories, Mindray Medical International, Siemens Healthneers, BioSystems, BioRad Laboratories, Horiba, Symex Corporation, Nihon Kohden Corpration, Danaher Corporation, F. Hoffman-La-Roche Ltd. are the top players in the Hematology Diagnostics Market.
A. Hospitals and Clinics segment is anticipated to emerge as an area of remunerative opportunities for the leading players in the market.
A. Globally, Europe would provide lucrative prospects for the Hematology Diagnostics market in the years ahead.